Concepts (178)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bile Acids and Salts | 9 | 2020 | 37 | 4.150 |
Why?
|
| Metabolomics | 10 | 2020 | 95 | 1.820 |
Why?
|
| Liver Cirrhosis | 3 | 2020 | 67 | 1.280 |
Why?
|
| Obesity | 4 | 2020 | 1151 | 1.240 |
Why?
|
| Liver | 6 | 2020 | 511 | 1.170 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2019 | 66 | 0.830 |
Why?
|
| Chenodeoxycholic Acid | 2 | 2020 | 3 | 0.810 |
Why?
|
| Ileum | 2 | 2020 | 20 | 0.800 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 539 | 0.720 |
Why?
|
| Metabolome | 3 | 2018 | 51 | 0.720 |
Why?
|
| Isoxazoles | 2 | 2020 | 15 | 0.710 |
Why?
|
| Intestinal Mucosa | 2 | 2020 | 134 | 0.690 |
Why?
|
| Deoxycholic Acid | 2 | 2019 | 8 | 0.680 |
Why?
|
| Bile Reflux | 1 | 2020 | 1 | 0.660 |
Why?
|
| Gastritis | 1 | 2020 | 13 | 0.660 |
Why?
|
| Lithocholic Acid | 1 | 2020 | 1 | 0.650 |
Why?
|
| Ursodeoxycholic Acid | 1 | 2020 | 6 | 0.650 |
Why?
|
| Hepatitis B, Chronic | 1 | 2020 | 16 | 0.650 |
Why?
|
| Tea | 1 | 2019 | 46 | 0.610 |
Why?
|
| Catechin | 1 | 2019 | 39 | 0.610 |
Why?
|
| Hypercholesterolemia | 1 | 2019 | 42 | 0.610 |
Why?
|
| Mass Spectrometry | 2 | 2018 | 280 | 0.600 |
Why?
|
| Liver Failure, Acute | 1 | 2018 | 5 | 0.580 |
Why?
|
| Hepatic Encephalopathy | 1 | 2018 | 9 | 0.580 |
Why?
|
| Ammonia | 1 | 2018 | 22 | 0.580 |
Why?
|
| Hepatitis B virus | 1 | 2018 | 18 | 0.570 |
Why?
|
| Chromatography, Liquid | 3 | 2018 | 182 | 0.570 |
Why?
|
| Caloric Restriction | 1 | 2018 | 34 | 0.570 |
Why?
|
| Cognition Disorders | 1 | 2020 | 243 | 0.570 |
Why?
|
| Hepacivirus | 1 | 2018 | 74 | 0.550 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 1 | 2017 | 5 | 0.530 |
Why?
|
| Stearic Acids | 1 | 2016 | 7 | 0.520 |
Why?
|
| Glucose Transporter Type 5 | 1 | 2016 | 1 | 0.510 |
Why?
|
| Mannitol | 1 | 2016 | 11 | 0.510 |
Why?
|
| Cytarabine | 1 | 2016 | 10 | 0.510 |
Why?
|
| Palmitic Acid | 1 | 2016 | 23 | 0.510 |
Why?
|
| Gastric Bypass | 1 | 2016 | 22 | 0.500 |
Why?
|
| Fructose | 1 | 2016 | 24 | 0.500 |
Why?
|
| Spectrometry, Mass, Electrospray Ionization | 1 | 2017 | 140 | 0.500 |
Why?
|
| Humans | 27 | 2020 | 43102 | 0.490 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 38 | 0.490 |
Why?
|
| Blood Glucose | 1 | 2018 | 389 | 0.490 |
Why?
|
| Animals | 13 | 2020 | 16992 | 0.490 |
Why?
|
| Lipids | 2 | 2020 | 256 | 0.490 |
Why?
|
| Mice | 8 | 2020 | 6644 | 0.480 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2017 | 465 | 0.450 |
Why?
|
| Male | 14 | 2020 | 23409 | 0.370 |
Why?
|
| Cohort Studies | 3 | 2020 | 1759 | 0.330 |
Why?
|
| Adult | 12 | 2020 | 13872 | 0.320 |
Why?
|
| Disease Models, Animal | 3 | 2020 | 1596 | 0.310 |
Why?
|
| Intestines | 2 | 2020 | 71 | 0.300 |
Why?
|
| Female | 13 | 2020 | 24698 | 0.280 |
Why?
|
| Circadian Rhythm | 3 | 2019 | 236 | 0.270 |
Why?
|
| Homeostasis | 2 | 2018 | 192 | 0.260 |
Why?
|
| Energy Metabolism | 2 | 2018 | 187 | 0.240 |
Why?
|
| Breast Neoplasms | 2 | 2016 | 1723 | 0.230 |
Why?
|
| Signal Transduction | 3 | 2019 | 2157 | 0.230 |
Why?
|
| Middle Aged | 8 | 2019 | 12222 | 0.220 |
Why?
|
| Insulin Resistance | 2 | 2017 | 201 | 0.220 |
Why?
|
| Cell Line | 2 | 2018 | 1410 | 0.210 |
Why?
|
| Mice, Inbred C57BL | 2 | 2020 | 1869 | 0.200 |
Why?
|
| Aged | 5 | 2020 | 8214 | 0.180 |
Why?
|
| China | 2 | 2020 | 229 | 0.180 |
Why?
|
| ROC Curve | 2 | 2018 | 159 | 0.170 |
Why?
|
| Glucose Transporter Type 3 | 1 | 2020 | 4 | 0.170 |
Why?
|
| Gastric Juice | 1 | 2020 | 3 | 0.170 |
Why?
|
| Digestion | 1 | 2020 | 14 | 0.160 |
Why?
|
| Glucose Transporter Type 1 | 1 | 2020 | 20 | 0.160 |
Why?
|
| Cholestenones | 1 | 2020 | 3 | 0.160 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2020 | 52 | 0.160 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2020 | 15 | 0.160 |
Why?
|
| Metagenomics | 1 | 2020 | 46 | 0.160 |
Why?
|
| Protein Kinases | 1 | 2020 | 100 | 0.160 |
Why?
|
| Amidohydrolases | 1 | 2019 | 12 | 0.160 |
Why?
|
| Lipogenesis | 1 | 2019 | 19 | 0.160 |
Why?
|
| Adipose Tissue, Brown | 1 | 2020 | 46 | 0.160 |
Why?
|
| Disease Susceptibility | 1 | 2020 | 101 | 0.150 |
Why?
|
| Fibroblast Growth Factors | 1 | 2019 | 36 | 0.150 |
Why?
|
| Neuropsychological Tests | 1 | 2020 | 284 | 0.150 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2019 | 20 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2016 | 1285 | 0.150 |
Why?
|
| Bacteroides | 1 | 2018 | 10 | 0.150 |
Why?
|
| Bacteroidetes | 1 | 2018 | 13 | 0.150 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2019 | 203 | 0.150 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 611 | 0.140 |
Why?
|
| Area Under Curve | 1 | 2018 | 95 | 0.140 |
Why?
|
| Metabolic Diseases | 1 | 2018 | 40 | 0.140 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 2853 | 0.140 |
Why?
|
| Cholesterol | 1 | 2019 | 232 | 0.140 |
Why?
|
| Gastrointestinal Tract | 1 | 2018 | 71 | 0.140 |
Why?
|
| Mice, Obese | 1 | 2017 | 42 | 0.140 |
Why?
|
| Hyperglycemia | 1 | 2018 | 61 | 0.140 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 93 | 0.140 |
Why?
|
| Disease Progression | 1 | 2020 | 667 | 0.130 |
Why?
|
| Models, Biological | 2 | 2018 | 712 | 0.130 |
Why?
|
| Cholestasis | 1 | 2017 | 12 | 0.130 |
Why?
|
| Gene Expression Regulation | 2 | 2020 | 1070 | 0.130 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 1081 | 0.130 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2017 | 19 | 0.130 |
Why?
|
| Protective Agents | 1 | 2017 | 26 | 0.130 |
Why?
|
| Lipid Metabolism | 1 | 2018 | 148 | 0.130 |
Why?
|
| Glucose Tolerance Test | 1 | 2017 | 75 | 0.130 |
Why?
|
| Discriminant Analysis | 2 | 2015 | 25 | 0.130 |
Why?
|
| Acetyltransferases | 1 | 2016 | 27 | 0.130 |
Why?
|
| Prognosis | 2 | 2016 | 861 | 0.130 |
Why?
|
| Infant Formula | 1 | 2016 | 17 | 0.130 |
Why?
|
| Least-Squares Analysis | 2 | 2015 | 45 | 0.130 |
Why?
|
| Pharmacogenetics | 1 | 2017 | 67 | 0.130 |
Why?
|
| Carbohydrates | 1 | 2016 | 32 | 0.130 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2016 | 34 | 0.130 |
Why?
|
| Longitudinal Studies | 1 | 2020 | 1063 | 0.130 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2016 | 6 | 0.130 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2016 | 21 | 0.130 |
Why?
|
| Hepatocytes | 1 | 2017 | 80 | 0.130 |
Why?
|
| Carcinoma, Endometrioid | 1 | 2016 | 20 | 0.130 |
Why?
|
| Internet | 1 | 2018 | 236 | 0.130 |
Why?
|
| Hypoglycemic Agents | 1 | 2018 | 184 | 0.120 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2016 | 5 | 0.120 |
Why?
|
| Milk, Human | 1 | 2016 | 51 | 0.120 |
Why?
|
| Hepatitis | 1 | 2016 | 11 | 0.120 |
Why?
|
| Biliary Atresia | 1 | 2016 | 7 | 0.120 |
Why?
|
| Triglycerides | 1 | 2016 | 147 | 0.120 |
Why?
|
| Plant Extracts | 1 | 2019 | 302 | 0.120 |
Why?
|
| Histamine | 1 | 2016 | 19 | 0.120 |
Why?
|
| Molecular Structure | 1 | 2018 | 570 | 0.120 |
Why?
|
| Neoplasms, Glandular and Epithelial | 1 | 2016 | 57 | 0.120 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 2017 | 388 | 0.120 |
Why?
|
| Amino Acids | 1 | 2016 | 148 | 0.120 |
Why?
|
| Drug Synergism | 1 | 2016 | 195 | 0.120 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 189 | 0.120 |
Why?
|
| Body Mass Index | 1 | 2020 | 925 | 0.120 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2016 | 74 | 0.120 |
Why?
|
| Young Adult | 4 | 2019 | 5080 | 0.120 |
Why?
|
| Multivariate Analysis | 2 | 2016 | 638 | 0.110 |
Why?
|
| Chronic Disease | 1 | 2018 | 549 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 968 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2020 | 512 | 0.110 |
Why?
|
| Up-Regulation | 1 | 2016 | 536 | 0.100 |
Why?
|
| Sphingomyelins | 1 | 2013 | 9 | 0.100 |
Why?
|
| Lysophosphatidylcholines | 1 | 2013 | 22 | 0.100 |
Why?
|
| Principal Component Analysis | 1 | 2013 | 87 | 0.100 |
Why?
|
| Alzheimer Disease | 1 | 2020 | 1001 | 0.090 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 415 | 0.090 |
Why?
|
| Treatment Outcome | 1 | 2016 | 1604 | 0.090 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 749 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 2676 | 0.070 |
Why?
|
| Neoplasms | 1 | 2018 | 1377 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2016 | 374 | 0.060 |
Why?
|
| HCT116 Cells | 1 | 2020 | 40 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 165 | 0.040 |
Why?
|
| Hydroxylation | 1 | 2019 | 12 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 347 | 0.040 |
Why?
|
| Glucose | 1 | 2020 | 244 | 0.040 |
Why?
|
| Microsomes, Liver | 1 | 2019 | 75 | 0.040 |
Why?
|
| 1-Naphthylisothiocyanate | 1 | 2017 | 1 | 0.030 |
Why?
|
| Bilirubin | 1 | 2017 | 18 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2019 | 457 | 0.030 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2016 | 83 | 0.030 |
Why?
|
| Rats, Wistar | 1 | 2017 | 283 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 26 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 1154 | 0.030 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 140 | 0.030 |
Why?
|
| Blood Pressure | 1 | 2019 | 666 | 0.030 |
Why?
|
| Postprandial Period | 1 | 2015 | 13 | 0.030 |
Why?
|
| Fasting | 1 | 2015 | 56 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 518 | 0.030 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2016 | 652 | 0.030 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 213 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2020 | 1455 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2016 | 972 | 0.030 |
Why?
|
| Computational Biology | 1 | 2016 | 327 | 0.030 |
Why?
|
| Cytokines | 1 | 2017 | 678 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2015 | 241 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 509 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2017 | 1271 | 0.020 |
Why?
|
| Infant | 1 | 2016 | 1175 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 1857 | 0.020 |
Why?
|
| Adolescent | 1 | 2016 | 6081 | 0.010 |
Why?
|